These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 20846318

  • 1. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ, Mendes MA, Bounthavong M, Christopher ML, Boggie D, Morreale AP.
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [Abstract] [Full Text] [Related]

  • 2. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
    Li H, Li X, Xie F.
    Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis).
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Trans Am Ophthalmol Soc; 2013 Sep; 111():56-69. PubMed ID: 24167325
    [Abstract] [Full Text] [Related]

  • 6. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, Lotery AJ, Downes SM, Chakravarthy U, Reeves BC, IVAN Study Investigators.
    BMJ Open; 2014 Jul 29; 4(7):e005094. PubMed ID: 25079928
    [Abstract] [Full Text] [Related]

  • 8. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Rapuano S, Boyer D.
    Am J Ophthalmol; 2020 Oct 29; 218():225-241. PubMed ID: 32565050
    [Abstract] [Full Text] [Related]

  • 9. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
    Goulart B, Ramsey S.
    Value Health; 2011 Oct 29; 14(6):836-45. PubMed ID: 21914503
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
    Hedden L, Kennecke H, Villa D, Johnston K, Speers C, Kovacic L, Renouf DJ, Peacock S.
    Eur J Cancer; 2012 Sep 29; 48(13):1969-76. PubMed ID: 22325838
    [Abstract] [Full Text] [Related]

  • 12. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC, Brown MM, Turpcu A, Rajput Y.
    Ophthalmology; 2015 Jul 29; 122(7):1416-25. PubMed ID: 25935787
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
    Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J.
    Clin Ther; 2012 Feb 29; 34(2):446-56. PubMed ID: 22289279
    [Abstract] [Full Text] [Related]

  • 18. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC, Lade RJ, Adewoyin T, Chong NV.
    Ophthalmology; 2008 Dec 29; 115(12):2192-8. PubMed ID: 18930556
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.